Effects of dopamine D1 ligands on eye blinking in monkeys: Efficacy, antagonism, and D1/D2 interactions

Journal of Pharmacology and Experimental Therapeutics

Volumn 311, Issue 3, 2004, Pages 1008-1015

  Jutkiewicz, Emily M ^a   Bergman, Jack ^b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 PHENYL 1H 3 BENZAZEPINE; 3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; 3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; ECOPIPAM; LEVODOPA; 4 PROPYL 9 HYDROXY 1,2,3,4A,5,6 HEXAHYDRONAPHTHOXAZINE; 4-PROPYL-9-HYDROXY-1,2,3,4A,5,6-HEXAHYDRONAPHTHOXAZINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; LIGAND; OXAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BLINKING; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVATION; EYE MOVEMENT; LIGAND BINDING; MONKEY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CEBIDAE; DOSE RESPONSE; DRUG INTERACTION; DRUG POTENTIATION;

ANIMALS; BLINKING; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; LIGANDS; OXAZINES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SAIMIRI;

EID: 10044260868     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.071092     Document Type: Article

References (38)

1. l receptor efficacy. Eur J Pharmacol 188:335-347.
2. 1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 213:259-267.
3. Bergman J, France CP, Holtzman SG, Katz JL, Koek W, and Stephens DN (2000) Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic and GABAAergic ligands. Psychopharmacology 152:67-84.
4. 2 receptor agonists on schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp Ther 273:40-48.
5. 1A dopamine receptor from Gs protein. Mol Pharmacol 56:989-996.
6. Caplan R, Guthrie D, and Komo S (1996) Blink rate in children with attention-deficit-hyperactivity disorder. Biol Psychiatry 39:1032-1038.
7. Deuschl G and Goddemeier C (1998) Spontaneous and reflex activity of facial muscles in dystonia, Parkinson's disease and in normal subjects. J Neurol Neurosurg Psychiatr 64:320-324.
8. 2 receptors in the MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 265:1387-1391.
9. Ebert D, Albert R, Hammon G, Strasser B, May A, and Merz A (1996) Eye-blink rates and depression. Neuropsychopharmacology 15:332-339.
10. 2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J Pharmacol Exp Ther 259:595-600.
11. 1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology 117:287-297.
12. 1 receptor agonists by squirrel monkeys. Psychopharmacology 125:97-104.
13. 1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur J Pharmacol 246:39-44.
14. 1 dopamine receptor in rat brain. J Neurochem 85:378-386.
15. Karson CN (1983) Spontaneous eye-blink rates and dopaminergic systems. Brain 106:643-653.
16. Karson C, Freed WJ, Kleinman JE, Bigelow LB, and Wyatt RJ (1981) Neuroleptics decrease blinking in schizophrenic subjects. Biol Psychiatry 16:679-682.
17. Kebabian JW and Calne DB (1979) Multiple receptors for dopamine. Nature (Lond) 277:93-96.
18. Kleven MS and Koek W (1996) Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomologous monkeys. J Pharmacol Exp Ther 279:1211-1219.
19. Kojima M, Shioiri T, Hosoki T, Sakai M, Bando T, and Someya T (2002) Blink rate variability in patients with panic disorder: new trial using audiovisual stimulation. Psychiatr Clin Neurosci 56:545-549.
20. Lawrence MS and Redmond DE (1991) MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys. Pharmacol Biochem Behav 38:869-874.
21. Martin MW, Scott AW, Johnston DE Jr, Griffin S, and Luedtke RR (2001) Typical antipsychotics exhibit inverse agonist activity at rat dopamine D1-like receptors expressed in SF9 cells. Eur J Pharmacol 420:73-82.
22. Nielsen EB, Randrup K, and Andersen PH (1989) Amphetamine discrimination: effects of dopamine receptor agonists. Eur J Pharmacol 160:253-262.
23. 35S]GTPγS binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40:826-837.
24. 1 agonist, SKF 38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur J Pharmacol 202:273-276.
25. 1 receptor agonists in squirrel monkeys. Eur J Pharmacol 260:237-241.
26. 2 agonists in squirrel monkeys. Psychopharmacology 116:9-18.
27. 1 agonists in rhesus monkeys. Pharmacol Biochem Behav 68:301-309.
28. Spealman RD, Bergman J, and Madras BK (1991a) Self-administration of the high affinity cocaine analog 2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane. Pharmacol Biochem Behav 39:1011-1013.
29. Spealman RD, Bergman J, Madras BK, and Melia KF (1991b) Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther 258:945-953.
30. 1 agonists. Psychopharmacology 133:283-292.
31. Tidey JW and Bergman J (1998) Drug discrimination in methamphetamine- trained monkeys: agonist and antagonist effects of dopaminergic drugs. J Pharmacol Exp Ther 285:1163-1174.
32. Undie AS, Weinstock J, Sarau HM, and Friedman E (1994) Evidence for a distinct D1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J Neurochem 62(5):2045-2048.
33. 1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytes. Eur J Pharmacol 269:121-125.
34. Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG, and O'Boyle KM (1995) Behavioural pharmacology of "D1-like" dopamine receptors: further subtyping, new pharmacological probes and interactions with "D-2-like" receptors. Prog Neuropsychopharmacol Biol Psychiatry 19:811-831.
35. Walters JR, Bergstrom DA, Carlson JH, Chase TN, and Braun AR (1987) D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science (Wash DC) 236:719-722.
36. 1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF 38393) agonists in primates vs. rodents. Eur J Pharmacol 242:165-172.
37. 1 agonists in monkeys. J Pharmacol Exp Ther 283:29-38.
38. Weed MR and Woolverton WL (1995) The reinforcing effect of dopamine D1 receptor agonists in rhesus monkeys. J Pharmacol Exp Ther 275:1367-1374.